Stocktoria
Scilex Holding Co SCLX
Scilex Holding Co (SCLX) earns a Piotroski F-score of 2/9 (weak financial health). It pays a dividend yielding 14.33% (safety: no dividend). FY2025 revenue was $30.3M at a -1236.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SCLX | Scilex Holding Co | 2/9 | — | — | -46.5% |
| DTIL | PRECISION BIOSCIENCES INC | 1/9 | -7.2 | — | -50.1% |
| XFOR | X4 Pharmaceuticals, Inc | 3/9 | -1.48 | — | — |
| MGX | Metagenomi Therapeutics, Inc. | 1/9 | -0.61 | — | -51.8% |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| ALEC | Alector, Inc. | 1/9 | -9.85 | — | -79.1% |
About Scilex Holding Co
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
FAQ
Is SCLX financially healthy?
Scilex Holding Co's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does SCLX pay a dividend, and is it safe?
Yes. Scilex Holding Co pays a dividend yielding about 14.33% with a None payout ratio, rated “no dividend” for safety.
How profitable is SCLX?
In FY2025, Scilex Holding Co had a net margin of -1236.4%.
Is SCLX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Scilex Holding Co: a Piotroski F-score of 2/9, a dividend yield of 14.33%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.